Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

Marco Vitolo, Vincenzo L. Malavasi, Marco Proietti, Igor Diemberger, Laurent Fauchier, Francisco Marin, Michael Nabauer, Tatjana S. Potpara, Gheorghe-Andrei Dan, Zbigniew Kalarus, Luigi Tavazzi, Aldo Pietro Maggioni, Deirdre A. Lane, Gregory Y.H. Lip, Giuseppe Boriani*, ESC-EHRA EORP-AF Long-Term General Registry Investigators, Albert Marni Joensen (Member of study group), Anders Gammelmark (Member of study group), Lars Hvilsted Rasmussen (Member of study group), Pia Thisted Dinesen (Member of study group)Sam Riahi (Member of study group), Stine Krogh Venø (Member of study group), Bodil Ginnerup Sørensen, Anne Marie Korsgaard (Member of study group), Karen Petrea Andersen (Member of study group), Camilla Fragtrup Hellum (Member of study group)

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

4 Citations (Scopus)


BACKGROUND: Cardiac troponins (cTn) have been reported to be predictors for adverse outcomes in atrial fibrillation (AF), patients, but their actual use is still unclear.

AIM: To assess the factors associated with cTn testing in routine practice and evaluate the association with outcomes.

METHODS: Patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry were stratified into 3 groups according to cTn levels as (i) cTn not tested, (ii) cTn in range (≤99th percentile), (iii) cTn elevated (>99th percentile). The composite outcome of any thromboembolism /any acute coronary syndrome/cardiovascular (CV) death, defined as Major Adverse Cardiovascular Events (MACE) and all-cause death were the main endpoints.

RESULTS: Among 10 445 AF patients (median age 71 years, 40.3% females) cTn were tested in 2834 (27.1%). cTn was elevated in 904/2834 (31.9%) and in-range in 1930/2834 (68.1%) patients. Female sex, in-hospital enrollment, first-detected AF, CV risk factors, history of coronary artery disease, and atypical AF symptoms were independently associated with cTn testing. Elevated cTn were independently associated with a higher risk for MACE (Model 1, hazard ratio [HR] 1.74, 95% confidence interval [CI] 1.40-2.16, Model 2, HR 1.62, 95% CI 1.28-2.05; Model 3 HR 1.76, 95% CI 1.37-2.26) and all-cause death (Model 1, HR 1.45, 95% CI 1.21-1.74; Model 2, HR 1.36, 95% CI 1.12-1.66; Model 3, HR 1.38, 95% CI 1.12-1.71).

CONCLUSIONS: Elevated cTn levels were associated with an increased risk of all-cause mortality and adverse CV events. Clinical factors that might enhance the need to rule out CAD were associated with cTn testing.

Original languageEnglish
JournalEuropean Journal of Internal Medicine
Pages (from-to)45-56
Publication statusPublished - May 2022

Bibliographical note

Copyright © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.


  • AF registry
  • Atrial fibrillation
  • Biomarkers
  • Death
  • Major adverse cardiovascular events
  • Troponins
  • outcomes


Dive into the research topics of 'Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry'. Together they form a unique fingerprint.

Cite this